Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study

Hepatology

Volumn 71, Issue 2, 2020, Pages 456-462

  Jonas, Maureen M ^a,b   Squires, Robert H ^c,d   Rhee, Susan M ^e   Lin, Chih Wei ^f   Bessho, Kazuhiko ^g   Feiterna Sperling, Cornelia ^h   Hierro, Loreto ⁱ   Kelly, Deirdre ^j   Ling, Simon C ^k   Strokova, Tatiana ^l   del Valle Segarra, Antonio ^m   Lovell, Sandra ^e   Liu, Wei ^e   Ng, Teresa I ^e   Porcalla, Ariel ^e   Gonzalez, Yuri Sanchez ^e   Burroughs, Margaret ^e   Sokal, Etienne ⁿ  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e ABBVIE INC   (United States)

^f AMGEN INC   (United States)

^g OSAKA UNIVERSITY HOSPITAL   (Japan)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^k HOSPITAL FOR SICK CHILDREN   (Canada)

^l FEDERAL RESEARCH CENTRE OF NUTRITION   (Russian Federation)

^m San Jorge Children s Hospital   (Puerto Rico)

ⁿ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLECAPREVIR PLUS PIBRENTASVIR; BENZIMIDAZOLE DERIVATIVE; GLECAPREVIR AND PIBRENTASVIR; PYRROLIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; SULFONAMIDE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MALE; MAXIMUM CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; OROPHARYNX PAIN; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; RHINOPHARYNGITIS; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; CHRONIC HEPATITIS C; CLINICAL TRIAL; DRUG COMBINATION; TREATMENT OUTCOME;

ADOLESCENT; BENZIMIDAZOLES; CHILD; DRUG COMBINATIONS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; PYRROLIDINES; QUINOXALINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 85070750444     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.30840     Document Type: Article

References (18)

1. Indolfi G, Hierro L, Dezsofi A, Jahnel J, Debray D, Hadzic N, et al. Treatment of chronic hepatitis C virus infection in children: a position paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:505-515.
2. HARVONI (ledipasvir and sofosbuvir) prescribing information. Foster City, CA: Gilead Sciences; 2015.
3. SOVALDI (sofosbuvir) tablets, for oral use [package insert]. Foster City, CA: Gilead Sciences.
4. Mavyret (glecaprevir/pibrentasvir) prescribing information. AbbVie, Inc.; 2017.
5. Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1–6 patients without cirrhosis. J Hepatol 2018;69:293-300.
6. Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062-1068.
7. Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study. Clin Infect Dis 2018;67:1010-1017.
8. Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, et al. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology 2018;67:514-523.
9. Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hezode C, et al. Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology 2018;67:1253-1260.
10. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001;39:800-812.
11. Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr 2003;3:329-341.
12. Centers for Disease Control and Prevention. Update: influenza activity in the United States during the 2017–18 season and composition of the 2018–19 influenza vaccine. MMWR Morb Mortal Wkly Rep 2018;67:634-642.
13. World Health Organization. Influenza update. January 8, 2018. https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/
14. Sokal EM, Bourgois A, Stephenne X, Silveira T, Porta G, Gardovska D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010;52:827-831.
15. Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005;41:1013-1018.
16. Balistreri WF, Murray KF, Rosenthal P, Bansal S, Lin CH, Kersey K, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017;66:371-378.
17. Wirth S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, Balistreri WF, Lin CH, et al. Sofosbuvir and ribavirin in adolescents 12–17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 2017;66:1102-1110.
18. Squires JE, Balistreri WF. Hepatitis C virus infection in children and adolescents. Hepatol Commun 2017;1:87-98.